Craft

CN Bio

Revenue

£3.5 M

FY, 2024

CN Bio Summary

Company Summary

Overview
CN Bio Innovations (formerly known as Zyoxel) is a company that develops organ-on-a-chip systems for human drug discovery and preclinical research. It provides a platform for generating human-relevant efficacy, ADME (Absorption, Distribution, Metabolism, Excretion), and safety data.
Type
Subsidiary
Status
Active
Founded
2008
HQ
Milton, GB | view all locations
Website
https://cn-bio.com/
Cybersecurity rating
Sectors

Key People

  • Paul Brooks

    Paul Brooks, Chief Executive Officer

  • Tomasz Kostrzewski

    Tomasz Kostrzewski, Chief Scientific Officer

  • Emily Drea
  • Deepak Singh

    Deepak Singh, VP – Sales & Marketing

LocationsView all

1 location detected

  • Milton, England HQ

    United Kingdom

    332 Cambridge Science Park, Milton Rd

CN Bio Financials

Summary Financials

Revenue (FY, 2024)
£3.5M
Gross profit (FY, 2024)
£2.1M
Net income (FY, 2024)
(£6.3M)
Cash (FY, 2024)
£10.0M
EBIT (FY, 2024)
(£6.1M)

Footer menu